Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha6/11/2026Neutral
BFRI
Biofrontera IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$13.44M
P/E Ratio
—
EPS
$-0.98
Beta
0.82
52W High
$1.21
52W Low
$0.56
50-Day MA
$0.98
200-Day MA
$0.93
Dividend Yield
—
Profit Margin
-25.70%
Forward P/E
13.64
PEG Ratio
—
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Fundamentals
| Revenue (TTM) | $43.20M |
| Gross Profit (TTM) | $33.39M |
| EBITDA | $-10.56M |
| Operating Margin | -39.00% |
| Return on Equity | -339.00% |
| Return on Assets | -32.40% |
| Revenue/Share (TTM) | $3.97 |
| Book Value | $0.51 |
| Price-to-Book | 2.29 |
| Price-to-Sales (TTM) | 0.31 |
| EV/Revenue | 0.354 |
| EV/EBITDA | -0.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.40% |
| Shares Outstanding | $12.80M |
| Float | $9.08M |
| % Insiders | 13.18% |
| % Institutions | 22.42% |
Historical Volatility
HV 10-Day
47.30%
HV 20-Day
73.66%
HV 30-Day
83.08%
HV 60-Day
86.15%
HV Rank
69.0%
Volatility is currently contracting
Latest News
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
GlobeNewsWire5/21/2026Neutral
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.
Zacks Investment Research5/14/2026Neutral
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protection Actinic Keratosis affects an estimated 58 million Americans and, if left untreated, can develop into squamous cell carcinoma1 Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its second consecutive year.
GlobeNewsWire5/13/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BFRI and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026